Glomerulopathy from C3, Iptacopan obtains AIFA refunds for kidney disease
MILAN (ITALPRESS) – The Italian Pharmaco Agency (AIFA) has admitted to the Iptacopan Refundability, the first oral inhibitor of Factor B of the alternative supplement, first in its class, for the treatment of adults with glomerulopathy from C3. This result, […]
Glomerulopathy from C3, Iptacopan obtains AIFA refunds for kidney disease Read More »










